{"ATC Code":"N05BA04","Abbreviation":"","Aliases":["Droxacepam","Zaxopam","Ansioxacepam","Durazepam","Noctazepam","Psiquiwas","Quilibrex","Anxiolit","Aplakil","Astress"],"Biological Half-Life":"The mean elimination half-life of oxazepam is 8.2 hours.","CAS":"604-75-1","ChEBI":"CHEBI:7823","ChEMBL":"CHEMBL568","ChemicalClasses":["benzodiazepine"],"Chirality":"racemic","Classes":null,"Color/Form":"Crystals from alcohol","DEA no":2835,"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","Drug Indication":"Oxazepam is indicated for the management of anxiety disorders and for the short-term relief of symptoms of anxiety. It may also be used in the management of alcohol withdrawal symptoms.","Drug Warnings":"Late third trimester use and exposure during labor seems to be associated with much greater risks to the fetus and neonate. Some infants exposed at this time exhibit either the floppy infant syndrome or marked neonatal withdrawal symptoms. Symptoms vary from mild sedation, hypotonia, and reluctance to suck, to apneic spells, cyanosis, and impaired metabolic responses to cold stress. These symptoms have been reported to persist for periods from hours to months after birth. This correlates well with the pharmacokinetic and placental transfer of the benzodiazepines and their disposition in the neonate. /Benzodiazepines/","DrugClasses":[],"DurationOfAction":"6 - 12 hours","EINECS":"210-076-9","EliminationHalfLife":"6–9 hours[https://www.has-sante.fr/upload/docs/application/pdf/2011-11/mama_troubles_comportement_encadre_1_anxiolitiques.pdf Encadré  1.  Anxiolytiques  à  demi-vie  courte  (\u003c  20  heures)  et  sans  métabolite  actif  par  ordre alphabétique de DCI]\u003ca href='#cite_note-4'\u003e\u003csup\u003e[4]\u003c/sup\u003e\u003c/a\u003e\u003ca href='#cite_note-5'\u003e\u003csup\u003e[5]\u003c/sup\u003e\u003c/a\u003e","Erowid Experience Reports":[{"Id":"114783","Title":"No Permanent Fix--Except for Muscle Tension"}],"Esters":["acetate"],"European Community (EC) Number":"210-076-9","FDA Pharmacological Classification":"6GOW6DWN2A","FullSalts":["Oxazepam potassium","Oxazepam hydrochloride"],"HMDB ID":"HMDB0014980","HeavyAtomCount":20,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","IUPACName":"7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one","Impurities":["oxazepam benzophenone","oxazepam acetate","demoxepam","3-dehydroxy-3-oxo-4,5-dihydro oxazepam","6-chloro-4-phenylquinazoline-2-carbaldehyde"],"InChI":"InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)","InChIKey":"ADIMAYPTOBDMTL-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)","Melting Point":"401 to 403 °F (NTP, 1992)","MolecularFormula":"C\u003csub\u003e15\u003c/sub\u003eH\u003csub\u003e11\u003c/sub\u003eClN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"286.71 g/mol","Odor":"PRACTICALLY ODORLESS","Opticalactivity":"( + / - )","Pharmacodynamics":"Benzodiazepines, including oxazepam, exert their sedative and anxiolytic effects by potentiating the effects of endogenous GABA, the primary inhibitory neurotransmitter in the CNS. Compared to other benzodiazepines, it has relatively low potency and a moderate duration of action. Oxazepam should be administered with caution to patients for whom a drop in blood pressure may lead to cardiac complications as, in rare cases, it may cause hypotension.","Physical Description":"Oxazepam appears as odorless creamy-white to pale-yellow powder or white crystalline solid. Bitter taste. pH (2% aqueous suspension) 4.8-7. (NTP, 1992)","PrevSalts":["potassium","hydrochloride"],"PubChemId":4616,"Record Description":["Oxazepam can cause cancer according to The National Toxicology Program. It can cause developmental toxicity according to state or federal government labeling requirements.","Oxazepam appears as odorless creamy-white to pale-yellow powder or white crystalline solid. Bitter taste. pH (2% aqueous suspension) 4.8-7. (NTP, 1992)","Oxazepam is a 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5. It has a role as a xenobiotic, an environmental contaminant and an anxiolytic drug. It is a 1,4-benzodiazepinone and an organochlorine compound.","Oxazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. It is an active metabolite of both [diazepam] and [temazepam] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions.","Oxazepam is a Benzodiazepine.","Oxazepam is an orally available benzodiazepine used in the therapy of anxiety and acute alcohol withdrawal syndromes. As with most benzodiazepines, oxazepam has not been associated with serum aminotransferase or alkaline phosphatase elevations during therapy, and clinically apparent liver injury from oxazepam has not been reported and must be very rare, if it occurs at all.","Oxazepam is a synthetic benzodiazepine derivative with anxiolytic and sedative hypnotic properties. Although the mechanism of action has not been fully elucidated, oxazepam appears to enhance gamma-aminobutyric acid (GABA) receptor affinity for GABA, thereby prolonging synaptic actions of GABA.","OXAZEPAM is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.","Oxazepam is only found in individuals that have used or taken this drug. It is an intermediate-acting benzodiazepine used to treat alcohol withdrawal and anxiety disorders. Similar to other benzodiazepines, oxazepam exerts its anxiolytic effects by potentiating the effect of gamma-aminobutyric acid (GABA) on GABA-A receptors through a cooperative mechanism of action. GABA receptors are ionotropic chloride-linked channel receptors that produce inhibitory postsynaptic potentials. When activated by GABA, the GABA receptor/chloride ionophore complex undergoes a conformational change that allows the passage of chloride ions through the channel. Benzodiazepines are believed to exert their effect by increasing the effect of GABA at its receptor. Benzodiazepine binding increases chloride conductance in the presence of GABA by increasing the frequency at which the channel opens. In contrast, barbiturates increase chloride conductance in the presence of GABA by prolonging the time in which the channel remains open. There are 18 subtypes of the GABA receptor subunits. The \u0026alpha;\u003csub\u003e2\u003c/sub\u003e subunit of the \u0026alpha;\u003csub\u003e2\u003c/sub\u003e\u0026beta;\u003csub\u003e3\u003c/sub\u003e\u0026gamma;\u003csub\u003e2\u003c/sub\u003e receptor complex is thought to mediate anxiolytic effects while the \u0026alpha;\u003csub\u003e1\u003c/sub\u003e subunit of the \u0026alpha;\u003csub\u003e1\u003c/sub\u003e\u0026beta;\u003csub\u003e2\u003c/sub\u003e\u0026gamma;\u003csub\u003e2\u003c/sub\u003e receptor complex is thought to mediate sedative, anticonvulsant and anterograde amnesia effects. Oxazepam is also the metabolite of other benzodiazpines.","A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.","See also: Oxazepam Hemisuccinate (is active moiety of); Oxazepam hydrochloride (is active moiety of).","Oxazepam can cause cancer according to The National Toxicology Program. It can cause developmental toxicity according to state or federal government labeling requirements.","Oxazepam is a 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5. It has a role as a xenobiotic, an environmental contaminant and an anxiolytic drug. It is a 1,4-benzodiazepinone and an organochlorine compound.","LiverTox|CNS|Sedative/Hypnotic|Benzodiazepine"],"RefCount":6,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Oxazepam","Name":"Oxazepam","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q412299","Name":"Oxazepam","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00842","Name":"Oxazepam","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/4616","Name":"Oxazepam","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/667436","Name":"(+)-Oxazepam","Sub":true},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/921299","Name":"(-)-Oxazepam","Sub":true}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL568","Name":"Oxazepam","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1743322","Name":"(+)-Oxazepam","Sub":true},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1908107","Name":"(-)-Oxazepam","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7823","Name":"Oxazepam","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=604-75-1","Name":"Oxazepam","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=40762-00-3","Name":"(+)-Oxazepam","Sub":true},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=52432-54-9","Name":"(-)-Oxazepam","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014980","Name":"Oxazepam","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07359","Name":"Oxazepam","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/6GOW6DWN2A","Name":"Oxazepam","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/7RM38L3JWY","Name":"(+)-Oxazepam","Sub":true},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/7MLA6YZ8XW","Name":"(-)-Oxazepam","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID1021087","Name":"Oxazepam","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 4616, Oxazepam. Accessed June 25, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/4616\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/4616\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Oxazepam. UNII: 6GOW6DWN2A. Global Substance Registration System. Accessed June 25, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6GOW6DWN2A\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/6GOW6DWN2A\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed June 25, 2025. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e","Sonne J, Loft S, Døssing M, Vollmer-Larsen A, Olesen KL, Victor M, Andreasen F, Andreasen PB. Bioavailability and pharmacokinetics of oxazepam. European Journal of Clinical Pharmacology. 1988; 35(4):385–389.","Sonne J, Boesgaard S, Poulsen HE, Loft S, Hansen JM, Døssing M, Andreasen F. Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. British Journal of Clinical Pharmacology. November 1, 1990; 30(5):737–742."],"SMILES":"C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O","Salts":["potassium","hydrochloride"],"SaltsAcidCount":[1,1],"SaltsAmineCount":[0,1],"SaltsUNII":["U24E5Y7BVU","ZC7746T754"],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"S4 substance"},{"gov":"Brazil","ref":["3"],"schedule":"B1 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule IV substance"},{"gov":"Germany","ref":[],"schedule":"prescription only/Anlage III substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"}],"Solubility":"less than 1 mg/mL at 66 °F (NTP, 1992)","Stability/Shelf Life":"STABLE IN LIGHT","StereoisomerRacemic":"(RS)-Oxazepam","Stereoisomers":["(+)-Oxazepam","(-)-Oxazepam"],"StereoisomersUNII":["7RM38L3JWY","7MLA6YZ8XW"],"StoreUNII":["6GOW6DWN2A"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="91.494mm" version="1.2" viewBox="0 0 100.665 91.494" width="100.665mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="92.0" stroke="none" width="101.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <g class="bond" id="mol1bnd1">
                        
                <line x1="46.705" x2="61.276" y1="90.439" y2="85.943"/>
                        
                <line x1="47.331" x2="59.211" y1="87.694" y2="84.029"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd2" x1="61.276" x2="64.662" y1="85.943" y2="71.084"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="64.662" x2="53.476" y1="71.084" y2="60.721"/>
                        
                <line x1="61.971" x2="52.851" y1="71.916" y2="63.465"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="53.476" x2="38.906" y1="60.721" y2="65.216"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="38.906" x2="35.52" y1="65.216" y2="80.075"/>
                        
                <line x1="40.97" x2="38.21" y1="67.131" y2="79.244"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="46.705" x2="35.52" y1="90.439" y2="80.075"/>
                  
            <line class="bond" id="mol1bnd7" x1="53.476" x2="56.862" y1="60.721" y2="45.861"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="56.862" x2="68.391" y1="45.861" y2="43.176"/>
                        
                <line x1="57.464" x2="67.838" y1="43.217" y2="40.802"/>
                      
                <line class="hi" stroke="#3050F8" x1="68.391" x2="62.62650000000001" y1="43.176" y2="44.5185"/>
                <line class="hi" stroke="#3050F8" x1="67.838" x2="62.650999999999996" y1="40.802" y2="42.0095"/>
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="73.482" x2="78.299" y1="38.696" y2="28.691"/>
                  
            <line class="bond" id="mol1bnd10" x1="78.299" x2="71.695" y1="28.691" y2="14.975"/>
                  
            <g class="bond" id="mol1bnd11">
                        
                <line x1="70.379" x2="77.799" y1="14.668" y2="5.406"/>
                        
                <line x1="72.282" x2="79.702" y1="16.193" y2="6.931"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="77.799" x2="74.089" y1="5.405999999999999" y2="10.036999999999999"/>
                <line class="hi" stroke="#FF0D0D" x1="79.702" x2="75.99199999999999" y1="6.931000000000001" y2="11.562000000000001"/>
            </g>
                  
            <line class="bond" id="mol1bnd12" x1="71.695" x2="60.166" y1="14.975" y2="12.29"/>
                  
            <line class="bond" id="mol1bnd13" x1="53.83" x2="44.975" y1="13.957" y2="21.071"/>
                  
            <g class="bond" id="mol1bnd14">
                        
                <line x1="44.975" x2="44.975" y1="36.311" y2="21.071"/>
                        
                <line x1="42.536" x2="42.536" y1="34.903" y2="22.479"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd15" x1="56.862" x2="44.975" y1="45.861" y2="36.311"/>
                  
            <line class="bond" id="mol1bnd16" x1="44.975" x2="31.767" y1="36.311" y2="43.931"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="18.559" x2="31.767" y1="36.311" y2="43.931"/>
                        
                <line x1="20.997" x2="31.767" y1="34.903" y2="41.116"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="18.559" x2="18.559" y1="36.311" y2="21.071"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="31.767" x2="18.559" y1="13.451" y2="21.071"/>
                        
                <line x1="31.767" x2="20.997" y1="16.266" y2="22.479"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="44.975" x2="31.767" y1="21.071" y2="13.451"/>
                  
            <line class="bond" id="mol1bnd21" x1="18.559" x2="6.875" y1="36.311" y2="43.059"/>
                  
            <line class="bond" id="mol1bnd22" x1="78.299" x2="89.88" y1="28.691" y2="28.691"/>
                  
            <path class="atom" d="M73.636 44.857h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" fill="#3050F8" id="mol1atm8" stroke="none"/>
                  
            <path class="atom" d="M83.483 3.078q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM79.62 3.078q-.0 .923 .387 1.459q.392 .53 1.22 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.226 .524q-.393 .523 -.393 1.452z" id="mol1atm11" stroke="none"/>
                  
            <g class="atom" id="mol1atm12">
                        
                <path d="M58.802 13.97h-.72l-2.619 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M58.666 8.509h-.62v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.62v4.899z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M2.906 42.117q-.786 .0 -1.239 .53q-.452 .524 -.452 1.447q-.0 .911 .417 1.446q.422 .53 1.268 .53q.321 .0 .607 -.053q.292 -.06 .565 -.143v.536q-.273 .101 -.565 .148q-.292 .054 -.697 .054q-.744 -.0 -1.25 -.31q-.5 -.309 -.75 -.875q-.25 -.571 -.25 -1.339q.0 -.744 .268 -1.31q.274 -.565 .804 -.881q.529 -.321 1.279 -.321q.78 -.0 1.352 .285l-.244 .524q-.226 -.101 -.506 -.184q-.274 -.084 -.607 -.084zM5.662 46.541h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm19" stroke="none"/>
                  
            <g class="atom" id="mol1atm20">
                        
                <path d="M95.799 28.688q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.501 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM91.935 28.688q-.0 .923 .387 1.459q.393 .529 1.22 .529q.84 .0 1.221 -.529q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.453q-.381 -.523 -1.209 -.523q-.833 -.0 -1.226 .523q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M100.105 31.141h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="73.482" x2="75.8905" y1="38.696" y2="33.6935"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="60.166" x2="65.9305" y1="12.29" y2="13.6325"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="60.166" x2="65.9305" y1="12.29" y2="13.6325"/>
            <line class="hi" id="mol1bnd13" stroke="#3050F8" x1="53.83" x2="49.4025" y1="13.957" y2="17.514000000000003"/>
            <line class="hi" id="mol1bnd13" stroke="#3050F8" x1="53.83" x2="49.4025" y1="13.957" y2="17.514000000000003"/>
            <line class="hi" id="mol1bnd21" stroke="#1FF01F" x1="6.875" x2="12.717" y1="43.059" y2="39.685"/>
            <line class="hi" id="mol1bnd22" stroke="#FF0D0D" x1="89.88" x2="84.0895" y1="28.691" y2="28.691"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Taste":"BITTER","Therapeutic Uses":"Anti-Anxiety Agents, Benzodiazepine; GABA Modulators; Sedatives, Nonbarbiturate","Title":"Oxazepam","UNII":"6GOW6DWN2A","Wikidata":"Q412299","Wikipedia":"Oxazepam","XLogP":2.2,"pH":"BETWEEN 4.8 AND 7.0 (1 IN 50 SUSPENSION)"}